Compared to the general population, older adults are more at risk of experiencing adverse drug reactions. Why is this the case, and what does this mean for pharmacovigilance?


Medication-related-harm (MRH) is especially prevalent in older adults due to changing physiology as the body ages, increased frailty, and the incidence of polypharmacy in this patient group. Giovanni Furlan, Worldwide Safety Site Lead for Thessaloniki of Pfizer discusses what makes this patient group so vulnerable to adverse drug reactions, how poor representation and using age alone to define older adults exacerbates this problem, and suggests ways forward in monitoring drug safety in older patients.

You may also like


How diclofenac drove vultures to the brink and unleashed a rabies crisis

How one unusual crisis highlights the need to more effectively integrate the One Health approach and ecopharmacovigilance into pharmaceutical monitoring and legislation.

20 August 2025

Rethinking Medical Device Safety in a Drug-Centric World

From software updates to complex human-machine interactions, medical devices pose safety challenges that require dedicated frameworks beyond drug vigilance.

28 August 2025

Strengthening healthcare systems against substandard medicines

Counterfeit drugs threaten millions worldwide, yet healthcare workers often lack training to spot fakes or report them, leaving this problem largely invisible.

01 October 2025